Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00511238
Status:
COMPLETED
Last Update Posted:
2017-08-31
First Post:
2007-08-01
Brief Title:
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
An Open-label Single-arm Phase 2 Study of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma
Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment
Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None